It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The occurrence of psychological late effects resulting from the diagnosis and treatment of pediatric acute lymphoblastic leukemia (ALL) been the subject of empirical investigations for approximately 25 years, with an emphasis on those patients treated with radiation therapy. In more recent years, however, research has shown that children and adolescents with ALL treated only with chemotherapy may also be at risk for treatment-related cognitive and academic deficits, although many specific treatment regimens remain to be investigated. Purpose. The present investigation was designed to examine 76 pediatric patients with ALL who were randomized to receive 1g/m2 or 2g/m 2 of intravenous methotrexate (IVMTX) with regard to cognitive, academic, and social-emotional/behavioral functioning over a 3-year period beginning shortly after diagnosis. Method. Scores from a preexisting database were analyzed with particular interest in main effects for methotrexate dose level, time since diagnosis, age at diagnosis, ALL vs non-ALL status and interactions between group and time variables. Participants with ALL and group of non-ALL siblings had participated in cognitive evaluations measuring performance in the following domains: intelligence, language, visual-spatial/visual-motor skills, attention and working memory, processing speed, psychomotor speed and coordination, executive function, academic achievement, and social-emotional/behavioral functioning. Results. A main effect for methotrexate dose level was significant for a measure of adaptive skills. A main effect for age at diagnosis was noted on measures of visual-spatial attention and working memory, and spelling and written expression. No main effect for time was noted on any dependent measure. Additionally, no main effect for ALL versus non-ALL status was noted on any dependent measure. Conclusion. Overall the findings suggest that the treatment of ALL with 1g/m2 or 2g/m2 IVMTX does not significantly impact the incidence of late effects with regard to cognitive, academic, and social-emotional/behavioral functioning within the first 3 years post-diagnosis. Younger age at diagnosis may, however, contribute to differences in performance on measures of cognitive and academic functioning.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer